BostonGene Announces Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Presentation Highlights Utilizing Comprehensive Molecular Testing to Identify Genomic Drivers of Radiation-Induced Sarcoma for Informed Therapeutic Decision-Making

WALTHAM, Mass – October 31, 2023BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its abstract has been accepted for poster presentation at the 2023 CTOS Annual Meeting being held November 1-4, 2023, in Dublin, Ireland.

Details of the presentation are as follows:

Abstract number: P420
Title: Comprehensive Molecular Profiling and Tumor Microenvironment Characteristics of Radiation-Induced Sarcoma
Presenter: Lev Bedniagin, MD, BostonGene
Category: Sarcoma Biology & ‘Omics
Date and time: Thursday, November 2, 2023 | 5:30 PM – 6:30 PM

A late-onset complication of radiotherapy, radiation-induced sarcoma (RIS), is a rare tumor associated with chemotherapy resistance and poor prognosis. Although immune checkpoint inhibitors (ICIs) are recommended for several soft tissue tumors, their efficacy has not been demonstrated in RIS. BostonGene Tumor PortraitTM testing, including whole exome sequencing (WES) and RNA-seq was performed to characterize the tumor microenvironment (TME) composition and identify genomic drivers of RIS to guide therapeutic decision-making. Over 50% of RIS patients had an IE TME subtype, which indicated the probability of a favorable response to ICI.

Click here to learn more about 2023 CTOS Annual Meeting.

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases.  BostonGene’s concierge-service model provides customized client solutions using a multi-omic approach prioritized for real-world impact to optimize standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results.  BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at

Media Contacts:


Erin O’Reilly